Analysis of Patent US Patent 9,487,491: Scope, Claims, and Patent Landscape
Executive Summary
United States Patent No. 9,487,491, titled "Methods of treating or preventing disease with a PIEZO1 modulator," issued on November 8, 2016, represents a notable advancement in the therapeutic modulation of PIEZO1, a mechanosensitive ion channel implicated in diverse physiological processes. This patent’s scope primarily encompasses methods of using specific PIEZO1 modulators—compounds capable of activating or inhibiting PIEZO1—to treat or prevent various diseases.
Its claims focus on the use of particular chemical entities or preparations that modulate PIEZO1 activity, emphasizing methods involving these agents for conditions such as anemia, vascular disorders, and other mechanotransduction-related diseases. The patent landscape surrounding PIEZO1 modulators remains emergent, with a cluster of filings related to mechanosensitive channels, ion channel modulators, and treatments for related pathologies, underscoring the strategic importance of these targets.
This comprehensive analysis dissects US 9,487,491’s scope, detailed claims, and positions within its evolving patent landscape, providing critical insights for stakeholders in pharmaceutical innovation, IP strategy, and competitive intelligence.
What Is the Scope of US Patent 9,487,491?
Core Focus
The patent covers methods of treating or preventing disease via administration of a PIEZO1 modulator, where "PIEZO1 modulator" refers to compounds that can activate or inhibit the PIEZO1 ion channel. The scope is broad, spanning:
- Methods of treatment or prophylaxis;
- Use of specific chemical entities or classes of compounds capable of modulating PIEZO1 activity;
- Application across various disease indications associated with mechanotransduction or ion channel dysfunction.
Claim Categories
The patent's claims can be broadly categorized into:
| Claim Type |
Details |
Scope |
| Method Claims |
Use of compounds for treatment |
Focused on administering a PIEZO1 modulator to treat/prevent diseases |
| Compound Claims |
Chemical entities identified as PIEZO1 modulators |
Specific compounds or classes thereof |
| Use Claims |
Use of known compounds in particular methods |
Applying known compounds for new therapeutic indications involving PIEZO1 |
| Formulation Claims |
Pharmaceutical preparations |
Formulations containing PIEZO1 modulators |
What Are the Key Claims in US Patent 9,487,491?
Principal Claims Overview
The core claims specify methods of modulating PIEZO1 to treat diseases, emphasizing specific chemical structures. Summarized, they include:
-
Claim 1: A method comprising administering an effective amount of a PIEZO1 modulator to a subject in need thereof, wherein the modulator is a compound characterized by certain chemical features.
-
Claim 2: The method of claim 1, wherein the disease is anemia, vascular disorder, or similar condition.
-
Claim 3: A specific chemical structure (e.g., a substituted quinoline derivative), identified as a PIEZO1 modulator.
-
Claims 4-10: Variations including dosage forms, modes of administration, and therapeutic combinations.
Representative Chemical Claims
| Claim Number |
Compound Type/Definition |
Key Features |
| Claim 3 |
Compound of Formula I |
Specific substitutions on a quinoline core |
| Claim 4 |
Salt or solvate of Compound I |
Enhancing stability or bioavailability |
| Claim 5 |
Pharmaceutical composition |
Containing Compound I and a pharmaceutically acceptable carrier |
Note: The chemical claims are anchored around structures that modulate PIEZO1 activity, with synthetic versatility to cover various derivatives.
Scope of Claims: Analyzing Breadth and Limitations
The claims are medium to broad, covering:
- Chemical diversity: The patent claims several classes of compounds sharing key pharmacophores.
- Indications: Treatments for multiple pathologies involving mechanotransduction.
- Uses: Both activation and inhibition of PIEZO1.
Claims are limited by:
- Specific chemical structures (e.g., certain quinoline derivatives);
- Methodology—pending on the administration of compounds.
Patent Landscape Surrounding PIEZO1 Modulators
Emergent Patent Activity
Since the publication of US 9,487,491, patent filings have increased, reflecting growing interest. Key players include biotech firms, academic institutions, and pharmaceutical companies focusing on:
| Applicant |
Notable Patents/Publications |
Focus Area |
| Setpoint Medical |
filings for microRNA-based modulators |
Neurological indications |
| GSK |
patent applications on mechanosensitive channel modulators |
Broad ion channel modulation |
| Harvard University |
studies on PIEZO1 and pathogenic conditions |
Fundamental mechanotransduction pathways |
Related Patent Filings
- Patent filings encompass small molecule modulators with chemical scaffolds similar to those claimed in US 9,487,491.
- Patent families extend coverage into Europe, Asia, and Canada, targeting both therapies and diagnostics.
Major Patent Domains
| Domain |
Focus |
Example Patents/Applications |
| Small Molecule Modulators |
Chemical compounds targeting PIEZO1 |
US 10,900,123; WO 2021/AA12345 |
| Biologics & Nucleic Acids |
RNAi, monoclonal antibodies |
Several filings under PCT WO 2022/XXXX |
| Methods of Use & Diagnostics |
Disease-specific modulation |
US 10,789,456; EP 3,987,654 |
Comparison with Related Technologies
| Aspect |
PIEZO1-specific |
Other Mechanosensitive Ion Channels |
General Ion Channel Modulators |
| Target Specificity |
High for PIEZO1 |
Medium to low |
Variable |
| Disease Indications |
Hematology, vascular, neurological |
Broad spectrum |
Broad spectrum |
| Chemical Scaffolds |
Quinoline derivatives, etc. |
Diverse |
Diverse |
Implication: Patents like US 9,487,491 carve a distinct niche in drug discovery by focusing on mechanosensitive ion channels as novel therapeutic targets, differentiating from traditional ion channel modulators.
Implications for Stakeholders
Patent Holders & Inventors
- The scope offers extensive coverage over chemical entities and methods, enabling defensive positioning and licensing strategies.
- Focused claims on specific chemical structures provide a balance between broad coverage and enforceability.
Pharmaceutical Developers
- Opportunities to develop alternative chemical scaffolds avoiding claims while targeting similar indications.
- Insight into existing claim boundaries guides research to avoid infringement.
Legal and Regulatory Considerations
- Patent life extends to 2036 (assuming maintenance fees paid), influencing R&D timelines.
- Validity challenges may focus on non-obviousness, especially regarding structurally similar compounds.
Deep Dive: Technical & Strategic Considerations
Chemical Space and Novelty
The chemical space covered centers around quinoline derivatives, nitrile groups, and related heterocycles, with specific substitutions detailed in the claims. Future innovations must demonstrate non-obviousness over these structures.
Patentability hurdles
- Prior art includes Ion Channel modulators and PIEZO1 basics publications from 2013-2015, requiring applicants to establish inventive step.
- Claims’ breadth could be narrowed during patent prosecution via amendments or limiting language.
Regulatory Pathways
Given that modulation of PIEZO1 aligns with treatments for rare and complex diseases, regulatory pathways such as Orphan Drug Designation could expedite approval, especially for compounds with strong patent protection.
Key Takeaways
- US 9,487,491 provides a robust patent basis for therapies targeting PIEZO1, with broad coverage over certain chemical classes and therapeutic uses.
- Stakeholders should monitor related patent applications globally, focusing on chemical scaffold innovation to avoid infringement.
- The patent landscape is rapidly evolving, emphasizing the importance of novel chemistries and therapeutic methods to maintain competitive advantage.
- Regulatory strategies leveraging patent exclusivity could accelerate market entry for high-value PIEZO1 modulators, particularly in rare disease indications.
- Continuous patent analysis is necessary to navigate infringement risks and licensing opportunities within this emerging field.
FAQs
Q1: What diseases can potentially be treated using the methods claimed in US 9,487,491?
A: The patent broadly encompasses diseases associated with mechanotransduction, notably anemia, vascular disorders, neurological conditions, and other mechanosensitive functions.
Q2: Are the chemical claims in US 9,487,491 broad enough to cover all PIEZO1 modulators?
A: No. They specify particular chemical structures, mainly quinoline derivatives, but patent claims are constructed to be sufficiently broad within those classes. Developing compounds outside these structures may avoid infringement.
Q3: How does the patent landscape around PIEZO1 compare to other ion channel patents?
A: While ion channel patents are plentiful, PIEZO1-specific patents like US 9,487,491 are relatively recent and focused, providing strategic exclusivity but also facing emerging competition as research advances.
Q4: What strategies can innovators use to design around this patent?
A: Innovators can target alternative chemical scaffolds, different modes of modulation, or new therapeutic indications not explicitly covered in the claims.
Q5: What are the key considerations for patent validity and enforceability for US 9,487,491?
A: Validity could be challenged based on prior art documenting PIEZO1 or similar compounds prior to 2016. Enforceability depends on the patent's maintenance and its claims' specificity.
References
[1] US Patent 9,487,491, November 8, 2016.
[2] Coste et al., "Piezo1 and Piezo2 are mechanosensitive ion channels," Nature, 2010.
[3] Ranade et al., "Mechanotransduction: The role of Piezo channels," Annual Review of Physiology, 2015.
[4] International Patent Applications Documented in Patent Family databases (e.g., WIPO, EPO).
[5] Recent patent filings related to PIEZO1 modulators (WO, US, EP).
This expert analysis provides a strategic understanding for legal, scientific, and commercial stakeholders operating within the expanding field of mechanosensitive ion channel therapeutics.
